EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Publikation: Bog/antologi/afhandling/rapport › Rapport › Forskning › fagfællebedømt
Standard
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells pursuant to Article 13(5) of Regulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.
European Food Safety Authority, 2013.Publikation: Bog/antologi/afhandling/rapport › Rapport › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - RPRT
T1 - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells pursuant to Article 13(5) of Regulation (EC) No 1924/2006
AU - Publication, EFSA
AU - Tetens, Inge
PY - 2013
Y1 - 2013
N2 - Following an application from Zambon B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. The food that is the subject of the health claim, Monurelle®, which is a combination of 120 mg cranberry (Vaccinium macrocarpon) extract (including 36 mg proanthocyanidins) and 60 mg of ascorbic acid, is sufficiently characterised. The claimed effect proposed by the applicant is reduction of E.coli adhesion to uroepithelial cells. The Panel considers that reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells is a beneficial physiological effect. Several health claim applications on cranberry products standardised by their proanthocyanidin content have already been evaluated by EFSA with an unfavourable outcome. The Panel notes that no studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Monurelle® and reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. © European Food Safety Authority, 2013
AB - Following an application from Zambon B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. The food that is the subject of the health claim, Monurelle®, which is a combination of 120 mg cranberry (Vaccinium macrocarpon) extract (including 36 mg proanthocyanidins) and 60 mg of ascorbic acid, is sufficiently characterised. The claimed effect proposed by the applicant is reduction of E.coli adhesion to uroepithelial cells. The Panel considers that reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells is a beneficial physiological effect. Several health claim applications on cranberry products standardised by their proanthocyanidin content have already been evaluated by EFSA with an unfavourable outcome. The Panel notes that no studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Monurelle® and reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. © European Food Safety Authority, 2013
KW - Monurelle®
KW - Proanthocyanidins
KW - Urinary tract
KW - E.coli adhesion
KW - E.coli colonisation
KW - Health claims
U2 - 10.2903/j.efsa.2013.3082
DO - 10.2903/j.efsa.2013.3082
M3 - Report
BT - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells pursuant to Article 13(5) of Regulation (EC) No 1924/2006
PB - European Food Safety Authority
ER -
ID: 208955702